Cigarette smoking and theophylline metabolism: effects of phenytoin. 1987

J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal

The induction of theophylline clearance by phenytoin was investigated in 12 young male subjects (six nonsmokers and six cigarette smokers). Each subject received intravenous theophylline to determine baseline pharmacokinetics. This was followed by an intravenous loading dose of phenytoin sodium and oral maintenance dosing for 2 weeks, after which the intravenous theophylline study was repeated. Phenytoin concentrations were similar in nonsmokers (10.8 +/- 2.0 micrograms/ml) and smokers (11.5 +/- 0.9 micrograms/ml). Control theophylline elimination half-life was 35% less and clearance 88% greater in smokers than in nonsmokers. The proportionate changes in half-life (26.8% +/- 5.6% in smokers and 25.8% +/- 3.5% in nonsmokers) and clearance (48.0% +/- 10.1% in smokers and 39.7% +/- 7.2% in nonsmokers) as the result of phenytoin induction were similar in both groups. These results demonstrate that the induction of theophylline clearance by phenytoin is additive to that caused by cigarette smoking and provide support for the suggestion that theophylline metabolism is influenced by multiple polymorphisms.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D012907 Smoking Willful or deliberate act of inhaling and exhaling SMOKE from burning substances or agents held by hand. Smoking Behaviors,Smoking Habit,Behavior, Smoking,Behaviors, Smoking,Habit, Smoking,Habits, Smoking,Smoking Behavior,Smoking Habits

Related Publications

J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
March 1985, Clinical pharmacology and therapeutics,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
October 1981, Clinical pharmacology and therapeutics,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
January 1981, European journal of clinical pharmacology,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
January 1979, The Western journal of medicine,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
March 1983, Clinical pharmacology and therapeutics,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
July 1977, The American review of respiratory disease,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
September 1991, The Journal of pharmacy and pharmacology,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
June 1987, Nihon Kyobu Shikkan Gakkai zasshi,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
November 1982, The New England journal of medicine,
J J Crowley, and B J Cusack, and S G Jue, and J R Koup, and R E Vestal
January 1990, Atherosclerosis,
Copied contents to your clipboard!